Abstract| Volume 116, P86-87, December 2022

P057Levonorgestrel 52 mg intrauterine system efficacy and safety after eight years of use

      This paper is only available as a PDF. To read, Please Download here.


      To evaluate efficacy, safety, and bleeding with levonorgestrel 52 mg intrauterine system (IUS) use from more than eight years through 10 years.


      Eligible people aged 16–45 received a levonorgestrel 52 mg IUS (Liletta®) in a multicenter trial evaluating efficacy and safety. After IUS placement, we followed 1,568 participants aged 16–35 for up to 10 years and 146 participants aged 36–45 for up to eight years. The study closed after achieving a full eight-year dataset. We evaluated pregnancy rates, safety, and bleeding during years 9 and 10 of use. We defined absence of bleeding as no spotting or bleeding for the preceding 90 days.


      Three-hundred thirty-nine participants used the IUS for >8 years, including 166 for >8.5 years. At study closure, 83 and 77 participants reached 9 and 10 years of use, respectively. At 8, 9, and 10 years, 254 (75%), 64 (77%), and 44 (57%) participants, respectively, were <40 years old. No pregnancies occurred during years 9 and 10. Expulsion occurred in 1 (0.3%) participant, a partial expulsion at 9 years 19 days of use. No perforations, pelvic infections, or IUS-related serious adverse events were noted in this time period. Absence of bleeding was noted by 33 (40%) and 28 (36%) participants at years 9 and 10, respectively. No participants discontinued for bleeding complaints during the two-year time period.


      Limited data suggest continued efficacy and safety, and a good bleeding profile, with >8 through 10 years of continuous levonorgestrel 52 mg IUS use.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect